As the Company’s due diligence programs are nearly complete, settlement of the Panax acquisition is now expected within weeks.
"The only material change has been that the acquisition of the final 20% equity in Panax will only cost MGC Pharmaceuticals €600,000, reduced from €800,000 in the original deal terms as announced on 27 April 2016."
So, this still isn't settled. We wait longer.
MXC Price at posting:
4.3¢ Sentiment: Hold Disclosure: Held
